Table 2 Treatment type, outcome responses, and adverse events stratified by high vs. low inflammatory markers in those receiving anti-inflammatory therapy (N = 167)
Outcomes | High inflammatory markers group (N = 104) | Low to normal inflammatory markers group (N = 63) | p-value |
|---|---|---|---|
Prescribed medications | |||
• Anti-inflammatory agents | |||
- Corticosteroid (%) | 61 (58.7%) | 41 (65.1%) | 0.513 |
- AZA (%) | 10 (9.6%) | 4 (6.4%) | 0.572 |
- MMF (%) | 46 (44.2%) | 34 (54%) | 0.264 |
- RTX (%) | 21 (20.2%) | 7 (11.1%) | 0.141 |
- Biologics, other than RTX (%) | 7 (6.8%) | 1 (1.6%) | 0.261 |
- HCQ (%) | 15 (14.4%) | 4 (6.4%) | 0.136 |
- IVIg (%) | 3 (2.9%) | 2 (3.2%) | 1.000 |
- MTX (%) | 1 (0.96%) | 1 (1.6%) | 1.000 |
• Concomitant antifibrotics | 13 (12.5%) | 6 (9.5%) | 0.624 |
Duration of treatment at response evaluation (months, median [IQR1 to IQR3]) | 8.1 [4.8 to 14.6] | 6 [3.4 to 13.5] | 0.401 |
ILD-AE | 13 (12.5%) | 6 (9.7%) | 0.626 |
Death during course of treatment | 13 (12.5%) | 8 (12.7%) | 1.000 |
Proceed to rescue lung transplantation | 8 (7.7%) | 11 (17.5%) | 0.077 |
Response to treatment | 58 (55.8%) | 22 (34.9%) | 0.011 |
Adverse events from treatment | 35 (33.7%) | 32 (50.8%) | 0.035 |
• Leukemia | 7 (6.7%) | 3 (4.8%) | 0.744 |
• Neutropenia | 2 (1.9%) | 3 (4.8%) | 0.367 |
• Anemia | 22 (21.2%) | 21 (33.3%) | 0.101 |
• Thrombocytopenia | 7 (6.7%) | 8 (12.7%) | 0.264 |
• Hepatic injury | 12 (11.5%) | 8 (12.7%) | 0.811 |
• Nausea-vomiting | 4 (3.9%) | 1 (1.6%) | 0.651 |
• Diarrhea | 1 (0.96%) | 2 (3.2%) | 0.557 |
• Pneumonia | 2 (1.9%) | 3 (4.8%) | 0.367 |
• Other infection | 2 (1.9%) | 2 (3.2%) | 0.633 |
• Osteoporosis | 1 (0.96%) | 1 (1.6%) | 1.000 |
Adverse events leading to treatment discontinuation | 2 (1.9%) | 1 (1.6%) | 1.000 |
Adverse events leading to death | 0 (0%) | 0 (0%) | - |